Drug intelligence / Profile preview

napabucasin + temozolomide

Development stage: Unknown
Lead developer: Sumitomo Pharma America
Modality: Small Molecules
Administration: Oral

Overview

Napabucasin + temozolomide is a combination therapy being investigated for the treatment of recurrent or progressed glioblastoma multiforme (GBM). Napabucasin is a first-in-class cancer stemness inhibitor that suppresses cancer stemness by targeting STAT3-driven gene transcription. Temozolomide is a chemotherapy drug commonly used in the treatment of glioblastoma. The combination has shown encouraging anti-tumor activity in clinical trials, with a disease control rate of 55.5% and partial response rate of 44.4% in evaluable patients with recurrent glioblastoma.

Targets

CYP2C9 (Cytochrome P450 family 2 subfamily C member 9)STAT3 (Signal Transducer and Activator of Transcription 3)DNACYP1A2 (Cytochrome P450 1A2)

Beyond the preview

Go deeper on napabucasin + temozolomide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on napabucasin + temozolomide.

Explore the full profile